JAMA Oncology

10/28/2026

How should extension studies to clinical trials be interpreted?

Some see them as an important source of evidence on long-term safety and treatment durability. Others question their validity and whether they should be considered trials at all.

💭 Where do you stand? Cast your vote in the latest JAMA+ Trials poll and share your perspective.

📊 Take the poll: https://ja.ma/4iJrZT3

10/26/2026

📝 JAMA Oncology Patient Page: Supplements and Wellness Products During Care Many people with cancer may consider supplements or wellness products during treatment. Some hope to improve energy, support the immune system, reduce treatment side effects, or feel more in control during a difficult time. These products may include herbal supplements, detox cleanses, high-dose vitamin infusions, or products marketed online as immune support or natural wellness products. This Patient Page discusses safety when taking supplements and wellness products during cancer treatment.

This JAMA Oncology Patient Page discusses safety when taking supplements and wellness products during cancer treatment.

10/25/2026

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis?

10/24/2026

📑 JAMA Oncology Review: The treatment of older adults with for early-stage involves a complex decision-making process that weighs the competing risks of disease recurrence against the potential harms of treatment. While older adults continue to be underrepresented in therapeutic clinical trials, there is a growing body of evidence to support optimal management of each subtype of early-stage breast cancer, including novel strategies like adjuvant cyclin-dependent kinase 4/6 inhibitors in hormone receptor–positive disease, and the neoadjuvant use of pembrolizumab in triple-negative breast cancer. This review will help clinicians best use the available data and decision-making tools to support best practice for treating older adults with early-stage breast cancer and will highlight ongoing clinical trials aimed at optimizing medical care for this patient population.

This narrative review discusses chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage breast cancer.

10/23/2026

📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health.

Last year, we launched JAMA+ Women's Health, an initiative that offers expertly curated research and insights from work published in JAMA and the JAMA Network. An important goal of JAMA+ Women's Health is to shift the conversation about women’s health beyond the “usual” categories of reproductive health, pregnancy, menopause, and certain cancers.

To align with the 2027 International Women’s Day, JAMA and the JAMA Network journals will publish women’s health articles across the full spectrum of health care on March 8, 2027.

➡️ This call for papers will prioritize timely and novel research articles and opinion manuscripts. Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day.

🔗 Read the full editorial: https://ja.ma/4evzUkv

10/23/2026

In a comparative study of US clinical trial portfolios, federally sponsored trials were less likely than industry-sponsored trials to focus on single-agent drug therapies for treatment. Federal sponsors were more likely to evaluate nontreatment interventions, including prevention and supportive care, indicating complementary roles in the cancer research enterprise.

This comparative study of cancer clinical trial portfolios assesses differences between federal and industry sponsors in cancer clinical trial research.

10/23/2026

Presented at from JAMA:

📊 Research Summary: In low erythroblastic oncogene B 2 (ERBB2) advanced , trastuzumab rezetecan showed benefit in hormone receptor–positive and hormone receptor–negative disease, with more frequent hematologic toxicity than chemotherapy.

https://ja.ma/4k8TtCL

10/23/2026

Presented today at from JAMA:

💬 Editorial by Maria Fernanda Mosele, MD, and Fabrice André, MD, PhD: In with low erythroblastic oncogene B 2 (ERBB2) expression, trastuzumab rezetecan demonstrates clinically meaningful activity and adds to the growing class of ERBB2-directed antibody-drug conjugates. Its place in care remains uncertain because trastuzumab deruxtecan is already approved in a similar setting and no head-to-head comparison is available.

https://ja.ma/4kcT6ah

10/23/2026

Presented at from JAMA:

Among patients with low erythroblastic oncogene B 2 (ERBB2) advanced , trastuzumab rezetecan improved progression-free survival vs physician’s choice of chemotherapy.

Benefit was observed in both chemotherapy-naive patients and the overall population, supporting trastuzumab rezetecan as a potential treatment option in this setting.

🔗 Read the full trial: https://ja.ma/4k5jZwU

💬 Read the editorial by Maria Fernanda Mosele, MD, and Fabrice André, MD, PhD: https://ja.ma/4kafqRY

📊 Read the research summary: https://ja.ma/4ss7Vbm

10/22/2026

In Denmark, incidence increased substantially from 2010 to 2023, while rates of and remained stable. Most patients with meningioma received no treatment, which indicates that rising diagnosis did not translate into more intervention and has implications for resource planning in neuro-oncology care.

This quality improvement study examines incidence, treatment, and surveillance patterns in meningioma care in Denmark from 2010 to 2023 to identify potentially unnecessary follow-up imaging.